{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-037057","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.763507+00:00","generated_at":"2026-06-22T04:01:27.877094+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbCellera Q3 revenue $101.4M, net income $0.09/share; program starts up 33%","bullets":["Total revenue $101.4M (Q3 2021: $5.5M); net income $26.6M ($0.09 basic EPS) vs net loss $21.4M.","Bebtelovimab royalties contributed $93.3M; research fees $7.5M, milestones $0.4M, licensing $0.2M.","Cumulative program starts reached 92, up 33% from 69 in Q3 2021; partners increased to 38.","Cash, cash equivalents and marketable securities stood at $868M.","R&D expenses $26.6M (up 52% YoY) reflecting continued investment in discovery engine."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-037057","json":"https://secwatch.observer/filing/0001564590-22-037057.json","markdown":"https://secwatch.observer/filing/0001564590-22-037057.md","text":"https://secwatch.observer/filing/0001564590-22-037057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/0001564590-22-037057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/abcl-8k_20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:01:27.877094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7743b387eb84823196433493ecad52189a9a14f","claim":"AbCellera Biologics Inc. reported Q3 2022 results: revenue $101.4 million, net income $26.6 million, EPS $0.09 per share (basic) and $0.08 per share (diluted).","evidence_excerpt":"Total revenue of $101 million, compared to $6 million in Q3 2021 • Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 • Net earnings of $0.09 per share on a basic and $0.08 on a diluted basis, compared to a net loss of ($0.08) per share (basic and diluted) in Q3 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/0001564590-22-037057-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q3 2022"},{"label":"Revenue","value":"$101.4 million"},{"label":"Net income","value":"$26.6 million"},{"label":"EPS","value":"$0.09 per share (basic) and $0.08 per share (diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}